Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-25
2006-04-25
McKenzie, Thomas C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S254000
Reexamination Certificate
active
07034032
ABSTRACT:
The invention provides novel 1,2,3-triazolo[4,5-d]pyrimidine compounds, such as those represented by formula (I):their use as medicaments, particularly in platelet aggregation disorders, compositions containing them and processes for their preparation.
REFERENCES:
patent: 0 368 640 (1990-05-01), None
patent: WO 99/05143 (1999-02-01), None
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Storey, R.F. et al, Thromb. Haemost., 2001, 85(3), pp. 401-407, Medline Abstract PMID 11307804.
Brown Roger
Guile Simon
Pairaudeau Garry
Springthorpe Brian
AstraZeneca AB
Fish & Neave IP Group Ropes & Gray LLP
McKenzie Thomas C.
LandOfFree
Cyclopentan-2-ol-1-yl-[1,2,3]triazolo[4,5-D]pyrimidine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclopentan-2-ol-1-yl-[1,2,3]triazolo[4,5-D]pyrimidine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclopentan-2-ol-1-yl-[1,2,3]triazolo[4,5-D]pyrimidine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3527480